Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Acalabrutinib Is Viable Option for Ibrutinib-Intolerant Relapsed/Refractory CLL

June 21st 2019

Acalabrutinib elicited high rates of response as well as prolonged survival and was well tolerated in patients with chronic lymphocytic leukemia who demonstrated intolerance to ibrutinib.

Genetic Analysis Provides Insight Into Venetoclax/Obinutuzumab Benefit in Frontline CLL

June 20th 2019

In a careful evaluation of chemotherapy‐free regimens, the combination of obinutuzumab plus venetoclax compared to obinutuzumab plus chlorambucil, objective and complete response rates, as well as progression-free survival were superior with the venetoclax combination in the overall study population and across all genetic subgroups evaluated in patients with chronic lymphocytic lymphoma.

Efficacy Data Support Acalabrutinib Across CLL Settings

June 20th 2019

The phase III ASCEND trial is only one of the pivotal trials that have presented data to suggest that acalabrutinib (Calquence) could see an FDA approval for the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Barr on Updated RESONATE Data in IGHV-Mutant CLL

June 20th 2019

Paul Barr, MD, medical director, Cancer Center Clinical Trials Office, and assistant professor, School of Medicine and Dentistry, University of Rochester, discusses the 6-year follow-up in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) on ibrutinib (Imbruvica) as part of the RESONATE study.

Brown Highlights the Future of Acalabrutinib in CLL Treatment

June 20th 2019

Jennifer R. Brown, MD, PhD, highlights the new and upcoming research regarding acalabrutinib in the field of chronic lymphocytic leukemia.

Dr. Davids on the Use of CAR T-Cell Therapy in CLL

June 18th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of CAR T-cell therapy for the treatment of patients with chronic lymphocytic leukemia (CLL).

Single-Agent Acalabrutinib Showcases Potential Practice-Changing Data in Relapsed/Refractory CLL

June 17th 2019

Chemotherapy-free treatment with single-agent acalabrutinib provided a statistically significant and clinically meaningful improvement in progression-free survival compared with physicians’ choice of standard therapy in patients with previously treated chronic lymphocytic leukemia.

Acalabrutinib Monotherapy Safe, Significantly Improves PFS in Relapsed/Refractory CLL

June 16th 2019

Among the most highly anticipated study results to be presented during the 2019 European Hematology Association Congress were those of the phase III ASCEND trial, which investigated the use of acalabrutinib monotherapy in patients with previously-treated chronic lymphocytic leukemia.

Ibrutinib Significantly Prolongs PFS in Early-Stage CLL

June 16th 2019

Ibrutinib monotherapy significantly improved event- and progression-free survival compared with placebo in treatment-naïve patients with early-stage, asymptomatic chronic lymphocytic leukemia.

Dr. Tedeschi on Frontline Ibrutinib for Older Patients With CLL

June 16th 2019

Alessandra Tedeschi MD, Department of Hematology, Azienda Ospedaliera Niguarda Ca' Granda in Milan, Italy, discusses the long-term findings of the phase III RESONATE-2 trial during the 2019 European Hematology Association Congress.

Frontline Venetoclax/Obinutuzumab Combo Emerges as Treatment Option for CLL With CKT

June 15th 2019

Othman Al-Sawaf, MD, discusses findings from the CLL14 trial, the rationale for exploring this proposed combination, and shares his thoughts on the emerging treatment paradigms in chronic lymphocytic leukemia.

Frontline Ibrutinib Showcases Long-Term OS Benefit in Older Patients With CLL

June 15th 2019

Frontline therapy with ibrutinib was successfully administered for more than 60 months in patients with chronic lymphocytic leukemia aged 65 years and older and provided improved progression-free and overall survival compared with chlorambucil.

Acalabrutinib/Obinutuzumab Combo Improves PFS in Frontline CLL

June 6th 2019

The combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with obinutuzumab/chlorambucil in patients with previously untreated chronic lymphocytic leukemia, meeting the primary endpoint of the phase III ELEVATE-TN trial.

Acalabrutinib Combo Induces High Responses in CLL

June 5th 2019

Simultaneous targeting of Bruton’s tyrosine kinase and the CD20 antigen led to overall responses in more than 90% of patients with chronic lymphocytic leukemia, including untreated and relapsed/refractory disease.

Chemo-Free Combo Significantly Improves PFS in Previously Untreated CLL

June 4th 2019

The addition of venetoclax to obinutuzumab reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia.

Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL

June 4th 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Dr. Barrientos on Remaining Challenges in CLL

May 24th 2019

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses remaining challenges in the treatment of patients with chronic lymphocytic leukemia.

Expert Explains Expanding Post-Ibrutinib Options in CLL

May 24th 2019

Jacqueline C. Barrientos, MD, MS, highlights emerging agents in the post-ibrutinib landscape and overall next steps for advancing the field of CLL.

Dr. Brander on Targeted Agents in CLL

May 18th 2019

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses targeted agents in chronic lymphocytic leukemia (CLL).

Expanding the Utility of Novel Combination Regimens in CLL

May 17th 2019

Danielle M. Brander, MD, discusses the investigational combination treatments that are bringing patients with chronic lymphocytic leukemia one step closer to well-tolerated, time-limited therapy.